Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Sny crawled date : 2022 - 12 - 15 save search
Optinose Appoints Paul Spence as Chief Commercial Officer
Published: 2022-12-15 (Crawled : 22:00) - globenewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -2.35%
H: 0.0%
C: 0.0%
OPTN | $1.19 -2.46% -1.67% 510K
|
Health Services
|
| O: -4.0%
H: 5.95%
C: 1.19%
commercial
Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% -0.3% 1.8M
|
Health Technology
|
| O: -0.71%
H: 0.07%
C: -1.05%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
rare research global disease report growth market
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
pharmaceuticals health
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: -1.56%
day program
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
REGN | $898.56 -0.68% -0.71% 360K
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -2.26%
dupixent approved
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
REGN | $898.56 -0.68% -0.71% 360K
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: -2.26%
dupixent approved
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Everest Medicines announced that the company has achieved the preclinical proof-of-...
Published: 2022-12-15 (Crawled : 08:00) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
PRTA 4 | $21.99 -1.12% -1.14% 530K
|
Health Technology
|
| O: 0.97%
H: 7.04%
C: -0.02%
MTP | $0.4703 -70.79% -73.69% 0
|
Health Technology
|
| O: -4.03%
H: 2.0%
C: -15.78%
preclinical vaccine program mrna milestone
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
Published: 2022-12-15 (Crawled : 01:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.78%
H: 0.92%
C: -0.18%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.83%
H: 0.66%
C: 0.3%
treatment disease collaboration
Sinusitis drugs market size to increase by USD 801.39 million: 40% growth to originate from North America - Technavio
Published: 2022-12-14 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: -1.57%
H: 2.23%
C: 2.23%
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% -1.42% 1.4M
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: 0.36%
H: 0.28%
C: -1.17%
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
america sinusitis growth market
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
BRTX | $1.32 -1.49% 20.71% 3.3M
|
Professional, Scientific, and T...
PTN | $1.82 -5.21% 15.38% 290K
|
Health Technology
VIAO | $0.308 -26.67% 12.01% 390K
|
Electronic Technology
HNRA | $2.36 -9.58% 11.86% 220K
|
n/a
HYLN 4 | $1.32 -7.04% 8.33% 800K
|
Producer Manufacturing
UMAC | $1.85 -2.12% 8.11% 6.1K
|
BQ | $0.2429 -6.07% 6.63% 99K
|
Consumer Non-Durables
GORO F | $0.534 -0.6% 6.55% 630K
|
Non-Energy Minerals
LBRT 4 | $22.1 -1.6% 6.29% 2.1M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.